IceCure Medical reports results from clinical trial of ProSense for SRMs

IceCure Medical (ICCM) announced positive top-line results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses, or SRMs, in kidney cancer patients. A total of 114 patients were enrolled in the study, of whom 112 were evaluated at a median follow-up of four years. The study demonstrated that 83.9% of patients were recurrence-free at this median follow-up period. Among these patients, 12 underwent a second cryoablation procedure at a mean of 1.73+/-1.2 years. In a subgroup of patients with tumors less than or equal to3 cm, no prior kidney cancer, and successful initial procedures, the recurrence-free rate reached 89.4%. More detailed data from the study will be presented by Principal Investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology (“ECIO”), which will take place form April 26 to 30 in Basel, Switzerland. SRMs are increasingly detected due to increased imaging and represent a growing clinical challenge, particularly among elderly patients and those with comorbidities who are not suitable candidates for surgery. Minimally invasive, nephron-sparing treatment options that preserve kidney function, while effectively controlling tumors, are critically needed.